Lesinurad, a selective uric acid reabsorption inhibitor which is responsible for treating hyperuricemia associated with gout in patients. The current article focuses on the potential role of this approved drug. Gout is the most common form of inflammatory arthritis. It results from a metabolic disorder, hyperuricemia, where excessive concentrations of uric acid in the blood lead to deposition of monosodium urate crystals in and around the joints and other connective tissues.
Hyperuricemia is caused in most patients by inefficient uric acid excretion. It is also associated with comorbidities such as hypertension, cardiovascular disease, kidney disease, and metabolic syndrome, including diabetes. Hyperuricemia is primarily treated with xanthine oxidase inhibitors that block the production of uric acid. In addition, there are uricuretic agents that enhance therapeutic increases in uric…
